key: cord-0698440-iebb5qp1
authors: Matteo, Eleonora; Romoli, Michele; Calabrò, Calogero; Piccolo, Laura; Lazzarotto, Tiziana; Suserea, Manuela; Contardi, Sara; Stagni, Silvia; Gabrielli, Liliana; Forlivesi, Stefano; Bassi, Mirna; Borsari, Morena; Sacripanti, Chiara; Merli, Elena; Naldi, Federica; Kaveh, Keivan M.; Borghi, Annamaria; Magni, Elisabetta; Simonetti, Luigi; Descovich, Carlo; Vegezzi, Elisa; Gastaldi, Matteo; Zini, Andrea
title: Combined Central and Peripheral Demyelination with Anti-Neurofascin155 IgG Following COVID-19 Vaccination
date: 2021-12-13
journal: Can J Neurol Sci
DOI: 10.1017/cjn.2021.256
sha: 113577a43164ea2fd5792de6a07815087d90bc05
doc_id: 698440
cord_uid: iebb5qp1

nan

Combined central and peripheral demyelination (CCPD) is a rare demyelinating process that involves both the central and peripheral nervous system and can occur after infection or vaccination. 1 Here we describe the case of a patient that developed CCPD after having received the first dose of ChAdOx1 nCoV-19 vaccine.

A 52-year-old man with no significant comorbidities presented to the ER reporting sudden-onset tingling paresthesia in his fingers and toes, and reduced hand dexterity. Three weeks earlier, a COVID-19 outbreak had occurred in the penitentiary where he worked. Eleven days before admission, he was vaccinated with ChAdOx1 nCoV-19. At admission, the neurological examination showed VII cranial nerve deficit, dysarthria, and bilateral hand intrinsic muscles deficit (MRC = 4/5), normal deep tendon reflexes, and a slightly ataxic gait. Head and chest CT scan and blood exams were unremarkable. He was admitted to the Neurology Unit (Day 0). On Day 2, sensory disturbances worsened, reflexes became diffusely weak, and cranial nerves involvement became prominent with diplopia, perioral paresthesia, bilateral facial diplegia, dysphagia, hypophonia, and severe dysarthria. Cerebrospinal fluid (CSF) and brain magnetic resonance imaging (MRI) were unremarkable. Spine MRI revealed contrast enhancement of cauda equina roots ( Figure 1A ); electromyography showed a severe, distally predominant demyelinating polyradiculoneuropathy. He was started on intravenous immunoglobulin (IVIg), 0.4 g/kg for 5 days (days 3-7). On Day 4, hypercapnic respiratory failure required oxygen support in the intensive care unit.

Three days after IVIg start, he started to improve, and on Day 8, he was transferred to the Neurology Unit. On Day 11, he was weaned off oxygen via nasal cannula and started rehabilitation ( Figure 2 for clinical course). On Day 17, the patient reported blurred vision, especially in the right eye; three days later, he noted hypophonia and fatigability during speech. An ophthalmoscopic exam revealed bilateral optic papillitis; visual acuity was 8/10 right and 9/10 left. Visual evoked potentials showed bilateral slow conduction with right mild amplitude reduction. A second IVIg cycle did not provide substantial benefit. On day 28, brain MRI revealed contrast-enhancing multifocal bilateral demyelinating lesions ( Figure 1B -G). After 5 days of high-dose intravenous corticosteroids (1g die, Days 30-34), the patient completely recovered, and he was discharged with oral prednisone. After 2 months, he is clinically stable.

CSF examination on day 1 showed normal proteins and white blood cell count; cytoalbuminologic dissociation emerged on days 7 and 19.

Electromyography on day 1 showed severe, distally predominant, demyelinating symmetric polyradiculoneuropathy (DADS) with prolonged distal motor latency at lower limbs, diffuse reduction in nerve conduction velocity, absent F-waves in most of the explored nerves and increased temporal dispersion at lower limbs. On day 13 neurophysiological studies showed a slight worsening.

Serum and CSF IL-6 and IL-8 cytokines peaked during the first disease stage, decreasing thereafter ( Figure 2 ). Anti-spike antibodies progressively raised over time. Serum samples tested positive for anti-NF155 IgG autoantibodies and negative for anti-contactin-1, and anti-CNTN-1/CASPR-1 complex. IgG isotype determination is ongoing.

Infectious and other autoimmune screening was negative (see Supplementary Material Table 1 for full lab diagnostics).

The rise of the anti-spike protein title demonstrates a mounting immune response against SARS-CoV-2, which might have triggered an autoimmune process. Such finding seems to replicate the mechanisms of autoimmune-mediated complications of vaccination 2 and is in accordance with data from a large CCPD case series, where recent vaccination/infection triggered two-thirds of cases. 1 Peripheral nervous system (PNS) involvement can happen before, hand-in-hand with, or after central nervous system (CNS) involvement 1,3,4 and influences the first treatment choice, as those with early PNS involvement might receive IVIg/plasmapheresis rather than steroids. 1,4 CCPD has also been reported with anti-NF155 autoantibodies. 3, 4 This case exhibits some of the characteristic features of CCPD with anti-NF155 antibodies: the MS-like CNS involvement, with perivenular inflammation at periventricular sites ( Figure 1D) ; absence of oligoclonal bands in CSF; damage in nerve roots and DADS. 4 An attempt to better characterize the patient's immune response has been made by measuring cytokines levels both on serum and on CSF across the stay. The rise in IL-8 CSF levels (several times higher than serum) could point to an intrathecal autoimmune process, diverging from the pathogenesis of Guillain-Barré syndrome related to antiparanodal antibodies, with no oligoclonal bands and normal IgG indices. 5 The worldwide rollout of COVID-19 vaccines is eventually leading to the emergence of very rare syndromes after vaccination. Very rare events with unknown epidemiology are hardly interpretable in their relationship with vaccination. Here, although the temporal association of CCPD and vaccination does not prove any causal link, a connection with vaccine exposure must be considered, given the very rare nature of the syndrome and the negative findings emerging from all investigations. 

Statement of Authorship. AZ provided and cared for the study patient, acquired data, co-wrote the paper, revised and gave final approval to the manuscript, supervised the work; EM (Eleonora Matteo), CC, LP, MR: provided and cared for the study patient, acquired data, co-wrote the paper, revised and gave final approval to the manuscript; MS, SC: performed neurophysiology techniques, provided and cared for the study patient, revised and gave final approval to the manuscript; SS, LS: performed imaging diagnostic techniques, revised and gave final approval to the manuscript; TL, LG, MB, EV, MG: performed microbiological and/or immunological laboratory testing, revised and gave final approval to the manuscript; SF, EM (Elena Merli), FN, KK, AB: provided and cared for the study patient, revised, and gave final approval to the manuscript; MB, CS, CD: acquired data, revised and gave final approval to the manuscript.

Combined central and peripheral demyelination: clinical features, diagnostic findings, and treatment

Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination

A nationwide survey of combined central and peripheral demyelination in Japan

Anti-neurofascin autoantibody and demyelination

Antiparanodal antibodies and IgG subclasses in acute autoimmune neuropathy